Market Assessment
ChemoCentryx (CCXI) is a clinical-stage small market cap ($683M) biopharma developing innovative therapeutics predominantly for kidney diseases. Its scientific forte is chemokine biology. This is not surprising since Thomas Schall, PhD, the founder of ChemoCentryx, is a pioneer of chemokine biology and a world-leading expert on chemokine-based therapeutics. The potential clinical benefits of chemokine-based therapeutics are being progressively revealed in other disease states including NASH and HIV.
CCX140 is an orally bioavailable, potent, selective, small molecule CCR2 antagonist that inhibits CCR2 and blocks MCP-1-dependent monocyte activation and chemotaxis. CCR2 is